COMMUNIQUÉS West-GlobeNewswire

Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
12/03/2024
Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular [...]
Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock
12/03/2024
PURCHASE, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (“Cognition,” the “Company” or “We”) (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat [...]
Assure Holdings Enters into Agreement to Sell Certain of its Assets to MPOWERHealth
11/03/2024
DENVER, March 11, 2024 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative neuromonitoring (“IONM”) and remote neurology services, today announced that it [...]
Foundation Health Secures $6 Million in Seed Funding to Power the Next Generation of Consumer Healthcare Experiences
11/03/2024
Investment Accelerates the Development of SaaS Solutions Suite Featuring API-based Pharmacy and Telehealth Products SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- Foundation Health, a pioneering healthcare technology [...]
Appointment of Dr Darren Patti to Group Chief Operating Officer
11/03/2024
MELBOURNE, Australia, March 12, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce the appointment of Dr. Darren Patti as Group Chief Operating Officer (COO), [...]
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
11/03/2024
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist, with top-line data anticipated by year-end 2024 Enrollment ongoing for global Phase 2b trial to treat [...]
BioRestorative Therapies to Participate in the 36th Annual ROTH Conference
11/03/2024
MELVILLE, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative” or the “Company”) (NASDAQ: BRTX ) , a clinical stage company focused on stem cell-based therapies, today announced its [...]
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
11/03/2024
- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data in solid tumors anticipated in the 2nd half of 2024 - - CX-2051 (EpCAM ADC) Phase 1 clinical study initiation in solid tumors, including [...]
Eupraxia Pharmaceuticals Announces Overnight Marketed Offering of Approximately $30 Million
11/03/2024
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VICTORIA, British Columbia, March 11, 2024 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a [...]
Cognition Therapeutics Announces Proposed Public Offering of Common Stock
11/03/2024
PURCHASE, N. Y., March 11, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (“Cognition,” the “Company” or “We”) (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat [...]
Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
11/03/2024
WORCESTER, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell [...]
Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia
11/03/2024
Study will inform on long-term safety profile and tissue frataxin levels OLE initiated with 25 mg daily subcutaneous injections of nomlabofusp Frataxin data and safety data from the OLE study are intended to help [...]
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results
11/03/2024
Leadership Appointments Move Ocular Towards Being a Leader in Retinal Care Screening Underway in AXPAXLI™ Phase 3 SOL-1 Trial for Wet AMD Topline Clinical Data for AXPAXLI in Diabetic Retinopathy and PAXTRAVA™ in [...]
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results
11/03/2024
--Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Phase1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® ( [...]
LifeMD Reports Fourth Quarter 2023 Results
11/03/2024
Fourth quarter revenue increased 60% year-over-year to $44.9 million with Telehealth revenues increasing 90% versus the year-ago period. Adjusted EPS of $0.15 per share compared with $0.02 in the year-ago period. [...]
Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/03/2024
SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on March 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified [...]
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
11/03/2024
Presented initial Phase 1b data from three clinical programs that support potential best in class profiles, with ORIC-944 and ORIC-114 prioritized for further advancement towards registrational studies Initiation of [...]
SeaStar Medical-Sponsored Symposium Featuring Experts Discussing Pediatric Acute Kidney Injury and the Selective Cytopheretic Device to be Webcast Live at AKI & CRRT 2024
11/03/2024
March 13 webcast showcasing Quelimmune ™ scientific background and clinical data for pediatric AKI due to sepsis or a septic condition will be available on seastarmedical.com DENVER, March 11, 2024 (GLOBE NEWSWIRE) -- [...]
Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia
11/03/2024
FOSTER CITY, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product [...]

Pages